Previous studies identified KIAA1522 as a prognostic biomarker across multiple cancers, where it was linked to tumor progression, therapy resistance, and poor survival (Li et al., 2023; Liu et al., 2016; Wang et al., 2020; Xu et al., 2020). Here, NHSL3 is linked to neoplasm.